Companies: 10,795·Total market cap: $144.5T
BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOTNASDAQHealthcare● Active
$8.00
+$0.22(+2.83%)
Market Cap$640856832
P/E Ratio—
52W High$14.87
52W Low$7.6
SEC Filings

BridgeBio Oncology Therapeutics Inc. (BBOT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001869105 · BBOT · NASDAQ · as of Jun 10, 2026

Filing snapshot

155
Total Filings
424B3
Latest Form
2026-05-13
Most Recent
2025
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001869105 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001193125-26-094112
Primary Document
bbot-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001869105 · Accession 0001193125-26-094112

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-12Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
424B3424B3
424B3
2026-05-13
View
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
424B3424B3
424B3
2026-05-06
View
EFFECTEFFECT
EFFECT
2026-05-04
View
POS AMPOS AM
POS AM
2026-04-30
View
3Initial Statement of Beneficial Ownership
3
2026-04-30
View
3Initial Statement of Beneficial Ownership
3
2026-04-30
View
424B3424B3
424B3
2026-04-29
View
8-KCurrent Report
8-K
2026-04-29
View
ARSARS
ARS
2026-04-28
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
424B3424B3
424B3
2026-04-23
View
8-KCurrent Report
8-K
2026-04-23
View
Showing 1–15 of 125 filingsForm 4 / 144 hidden· 155 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001869105  |  Exchange: NASDAQ · Healthcare

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) has submitted 155 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001869105, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is BridgeBio Oncology Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent BridgeBio Oncology Therapeutics Inc. 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical BBOT 10-K annual reports are available from 2023 through 2026.

Investors researching BridgeBio Oncology Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
TNGX SEC Filings →ANAB SEC Filings →KOD SEC Filings →MNMD SEC Filings →SEPN SEC Filings →NRIX SEC Filings →URGN SEC Filings →XNCR SEC Filings →
→ BBOT Financials→ BBOT Earnings→ BBOT Insider Trades

Frequently Asked Questions

BBOT SEC Filings · 8 questions

BridgeBio Oncology Therapeutics Inc. (BBOT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 155 filings and access original documents at no cost. BridgeBio Oncology Therapeutics Inc.'s CIK is 0001869105.

BBOT SEC filingsBridgeBio Oncology Therapeutics Inc. SEC documentsfind BBOT 10-K